Amplea Therapeutics managing director and chief executive officer Dr Chris Burns. For everyday punters looking at medical technology companies, the best opportunities often come from identifying a drug that makes other multi-billion-dollar treatments work better. That is the main idea behind Melbourne-based medical company Amplia Therapeutics (ASX: ATX). While most cancer companies spend billions trying to make stronger, more toxic chemotherapies, Amplia is taking a dif

Amplia Therapeutics and the Australia New Zealand Gynaecological Group have announced a new ovarian cancer study. ASX-listed Amplia Therapeutics (ASX: ATX) is aggressively broadening its clinical reach, unveiling a major new collaboration to throw its lead drug candidate, narmafotinib, into the ring against ovarian cancer. The company has inked a deal with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to launch a new clinical study to evaluate its pro

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics, after the company unveiled results for a potential golden bullet for pancreatic cancer.